Greenwich Rx is recalling selected lots of compounded sterile medicines dispensed nationwide, including some prepared for Clove Rx. Patients and clinics with an affected product should stop using it immediately and discard it, according to the November 20 notice posted by FDA.

The Tomball, Texas, pharmacy says an FDA inspection and its own evaluation raised concerns about sterility assurance. A nonsterile medicine intended to be sterile can cause serious, potentially life-threatening infections. The company says it has found no evidence of contamination in the recalled products and has received no reports of adverse events related to this recall.

The affected medicines were dispensed from August 10 through September 21, 2026. Greenwich is mailing notices, but Clove customers should check their labels even without receiving a letter.

Match the product and lot

Four glass ampoules of sodium chloride solution in a white cardboard package
Saline-solution ampoules in an archive photograph from December 18, 2012. These are not recalled Greenwich or Clove products.Lee Haywood / Wikimedia Commons / CC BY-SA 2.0. Resized; display crop.

The pharmacy's searchable recall table identifies the formulation, strength, package size, lot number, beyond-use date and dispensing pharmacy. It includes selected semaglutide and tirzepatide combinations, NAD+ and other injections.

Examples in that table include:

  • Semaglutide/B12 Injection, 1mg/0.5mg/mL in a 1mL package, lot 0001-082526-1, beyond-use date December 3, 2026, dispensed through Greenwich Rx.
  • Semaglutide/B12 Injection, 10mg/0.5mg/mL in a 1mL package, lot 0005-081326-1, beyond-use date November 21, 2026, dispensed through Clove Rx.

These are examples, not the complete list. Use both filters on the pharmacy's table to check your product and dispensing pharmacy.

Sedgwick handles recall questions at 888-243-5547 or GreenwichRx6588@sedgwick.com, Monday through Friday, 8 a.m. to 5 p.m. Eastern. Contact your healthcare provider about problems that may be connected to an affected medicine.

FDA explains that compounded drugs are not FDA-approved: the agency does not review their safety, effectiveness or quality before marketing. The recall applies to the listed lots; a matching ingredient name alone does not identify an affected package.